PRVB - Provention Bio: PDUFA Ahead But Uncertainties Abound June, 23 2021 02:33 PM Provention Bio Inc. The Advisory Committee voted 10-7 favoring an approval recommendation for teplizumab. The FDA has given conflicting signals about approval. PDUFA is on July 2. For further details see: Provention Bio: PDUFA Ahead, But Uncertainties Abound